A new trading day began on Friday, with Caribou Biosciences Inc (NASDAQ: CRBU) stock price up 3.05% from the previous day of trading, before settling in for the closing price of $1.31. CRBU’s price has ranged from $1.22 to $8.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 71.11% over the past five years. Meanwhile, its annual earnings per share averaged -20.17%. With a float of $79.15 million, this company’s outstanding shares have now reached $90.55 million.
Let’s look at the performance matrix of the company that is accounted for 158 employees. In terms of profitability, gross margin is 69.15%, operating margin of -1439.5%, and the pretax margin is -1289.12%.
Caribou Biosciences Inc (CRBU) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Caribou Biosciences Inc is 12.60%, while institutional ownership is 59.84%. The most recent insider transaction that took place on Jan 29 ’25, was worth 24,651. In this transaction Chief Financial Officer of this company bought 17,360 shares at a rate of $1.42, taking the stock ownership to the 17,360 shares.
Caribou Biosciences Inc (CRBU) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.22% during the next five years compared to -37.16% drop over the previous five years of trading.
Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators
Here are Caribou Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.86 in one year’s time.
Technical Analysis of Caribou Biosciences Inc (CRBU)
Caribou Biosciences Inc (NASDAQ: CRBU) saw its 5-day average volume 0.99 million, a negative change from its year-to-date volume of 1.44 million. As of the previous 9 days, the stock’s Stochastic %D was 33.83%. Additionally, its Average True Range was 0.10.
During the past 100 days, Caribou Biosciences Inc’s (CRBU) raw stochastic average was set at 7.31%, which indicates a significant decrease from 37.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.08% in the past 14 days, which was lower than the 73.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6491, while its 200-day Moving Average is $2.0889. Nevertheless, the first resistance level for the watch stands at $1.4063 in the near term. At $1.4627, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.5058. If the price goes on to break the first support level at $1.3068, it is likely to go to the next support level at $1.2637. The third support level lies at $1.2073 if the price breaches the second support level.
Caribou Biosciences Inc (NASDAQ: CRBU) Key Stats
With a market capitalization of 122.25 million, the company has a total of 90,553K Shares Outstanding. Currently, annual sales are 34,480 K while annual income is -102,070 K. The company’s previous quarter sales were 2,020 K while its latest quarter income was -34,680 K.
